Orexigen acquires bupropion formulation rights from GSK
This article was originally published in Scrip
Executive Summary
Orexigen Therapeutics, a biopharmaceutical company focused on the treatment of obesity, has acquired non-exclusive rights to formulation patents related to bupropion from GlaxoSmithKline.